EHA 2024 | Pre-induction azacitidine and venetoclax to improve the bone marrow microenvironment in AML
Maher Salamoon, MD, Al-Baironi Hospital, Damascus, Syria, discusses the use of azacitidine and venetoclax prior to induction chemotherapy to enhance the bone marrow microenvironment in elderly patients with acute myeloid leukemia (AML). In a cohort of 20 patients receiving venetoclax and azacitidine for two months, bone marrow evaluations showed a significant reduction in malignant cells. Following this pre-induction phase, patients proceeded to chemotherapy, leading to a reduced induction mortality rate. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
